Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

NSPR vs ATEC vs SYK vs ANGO vs ZBH

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
NSPR
InspireMD, Inc.

Medical - Devices

HealthcareNASDAQ • IL
Market Cap$54M
5Y Perf.-90.8%
ATEC
Alphatec Holdings, Inc.

Medical - Devices

HealthcareNASDAQ • US
Market Cap$1.17B
5Y Perf.+74.2%
SYK
Stryker Corporation

Medical - Devices

HealthcareNYSE • US
Market Cap$112.69B
5Y Perf.+50.3%
ANGO
AngioDynamics, Inc.

Medical - Instruments & Supplies

HealthcareNASDAQ • US
Market Cap$469M
5Y Perf.+10.4%
ZBH
Zimmer Biomet Holdings, Inc.

Medical - Devices

HealthcareNYSE • US
Market Cap$16.32B
5Y Perf.-32.0%

NSPR vs ATEC vs SYK vs ANGO vs ZBH — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
NSPR logoNSPR
ATEC logoATEC
SYK logoSYK
ANGO logoANGO
ZBH logoZBH
IndustryMedical - DevicesMedical - DevicesMedical - DevicesMedical - Instruments & SuppliesMedical - Devices
Market Cap$54M$1.17B$112.69B$469M$16.32B
Revenue (TTM)$9M$595M$25.12B$307M$8.41B
Net Income (TTM)$-49M$-125M$3.25B$-28M$761M
Gross Margin29.5%89.6%63.5%53.7%70.0%
Operating Margin-5.5%-9.6%22.4%-9.4%15.6%
Forward P/E27.1x19.6x9.8x
Total Debt$2M$620M$14.86B$0.00$7.52B
Cash & Equiv.$9M$161M$4.01B$56M$592M

NSPR vs ATEC vs SYK vs ANGO vs ZBHLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

NSPR
ATEC
SYK
ANGO
ZBH
StockMay 20May 26Return
InspireMD, Inc. (NSPR)1009.2-90.8%
Alphatec Holdings, … (ATEC)100174.2+74.2%
Stryker Corporation (SYK)100150.3+50.3%
AngioDynamics, Inc. (ANGO)100110.4+10.4%
Zimmer Biomet Holdi… (ZBH)10068.0-32.0%

Price return only. Dividends and distributions are not included.

Quick Verdict: NSPR vs ATEC vs SYK vs ANGO vs ZBH

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: SYK leads in 4 of 7 categories (5-stock set), making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. InspireMD, Inc. is the stronger pick specifically for growth and revenue expansion. ANGO and ZBH also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
NSPR
InspireMD, Inc.
The Defensive Pick

NSPR is the #2 pick in this set and the best alternative if sleep-well-at-night is your priority.

  • Lower volatility, beta 0.85, Low D/E 4.0%, current ratio 5.74x
  • 28.1% revenue growth vs ANGO's -3.8%
Best for: sleep-well-at-night
ATEC
Alphatec Holdings, Inc.
The Growth Play

ATEC is the clearest fit if your priority is growth exposure.

  • Rev growth 25.0%, EPS growth 15.0%, 3Y rev CAGR 29.6%
Best for: growth exposure
SYK
Stryker Corporation
The Income Pick

SYK carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.

  • Dividend streak 34 yrs, beta 0.55, yield 1.1%
  • 187.1% 10Y total return vs ATEC's 225.4%
  • 12.9% margin vs NSPR's -5.4%
  • Beta 0.55 vs ANGO's 1.32
Best for: income & stability and long-term compounding
ANGO
AngioDynamics, Inc.
The Momentum Pick

ANGO ranks third and is worth considering specifically for momentum.

  • +28.5% vs NSPR's -54.5%
Best for: momentum
ZBH
Zimmer Biomet Holdings, Inc.
The Defensive Pick

ZBH is the clearest fit if your priority is defensive.

  • Beta 0.65, yield 1.1%, current ratio 1.98x
  • Better valuation composite
Best for: defensive
See the full category breakdown
CategoryWinnerWhy
GrowthNSPR logoNSPR28.1% revenue growth vs ANGO's -3.8%
ValueZBH logoZBHBetter valuation composite
Quality / MarginsSYK logoSYK12.9% margin vs NSPR's -5.4%
Stability / SafetySYK logoSYKBeta 0.55 vs ANGO's 1.32
DividendsSYK logoSYK1.1% yield, 34-year raise streak, vs ZBH's 1.1%, (3 stocks pay no dividend)
Momentum (1Y)ANGO logoANGO+28.5% vs NSPR's -54.5%
Efficiency (ROA)SYK logoSYK6.9% ROA vs NSPR's -88.7%, ROIC 11.4% vs -108.3%

NSPR vs ATEC vs SYK vs ANGO vs ZBH — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

NSPRInspireMD, Inc.
FY 2022
CGuard EPS
99.1%$5M
MGuard Prime EPS
0.9%$48,000
ATECAlphatec Holdings, Inc.
FY 2025
Products And Services
100.0%$764M
SYKStryker Corporation
FY 2025
MedSurg
62.3%$15.6B
Orthopaedics
37.7%$9.5B
ANGOAngioDynamics, Inc.
FY 2024
Med Device
65.0%$198M
Med Tech
35.0%$106M
ZBHZimmer Biomet Holdings, Inc.
FY 2025
Knees
43.9%$3.3B
S E T
28.4%$2.2B
Hips
27.7%$2.1B

NSPR vs ATEC vs SYK vs ANGO vs ZBH — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLSYKLAGGINGATEC

Income & Cash Flow (Last 12 Months)

SYK leads this category, winning 3 of 6 comparable metrics.

SYK is the larger business by revenue, generating $25.1B annually — 2797.2x NSPR's $9M. SYK is the more profitable business, keeping 12.9% of every revenue dollar as net income compared to NSPR's -5.4%. On growth, NSPR holds the edge at +61.6% YoY revenue growth, suggesting stronger near-term business momentum.

MetricNSPR logoNSPRInspireMD, Inc.ATEC logoATECAlphatec Holdings…SYK logoSYKStryker Corporati…ANGO logoANGOAngioDynamics, In…ZBH logoZBHZimmer Biomet Hol…
RevenueTrailing 12 months$9M$595M$25.1B$307M$8.4B
EBITDAEarnings before interest/tax-$49M$4M$6.3B-$5M$2.3B
Net IncomeAfter-tax profit-$49M-$125M$3.2B-$28M$761M
Free Cash FlowCash after capex-$37M$7M$4.3B-$9M$1.8B
Gross MarginGross profit ÷ Revenue+29.5%+89.6%+63.5%+53.7%+70.0%
Operating MarginEBIT ÷ Revenue-5.5%-9.6%+22.4%-9.4%+15.6%
Net MarginNet income ÷ Revenue-5.4%-21.1%+12.9%-9.0%+9.1%
FCF MarginFCF ÷ Revenue-4.1%+1.2%+17.1%-3.0%+21.8%
Rev. Growth (YoY)Latest quarter vs prior year+61.6%-100.0%+11.4%+9.0%+9.3%
EPS Growth (YoY)Latest quarter vs prior year+26.3%+37.1%+56.0%+42.3%+34.1%
SYK leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

ZBH leads this category, winning 4 of 6 comparable metrics.

At 23.5x trailing earnings, ZBH trades at a 33% valuation discount to SYK's 35.0x P/E. On an enterprise value basis, ZBH's 9.5x EV/EBITDA is more attractive than ATEC's 3752.1x.

MetricNSPR logoNSPRInspireMD, Inc.ATEC logoATECAlphatec Holdings…SYK logoSYKStryker Corporati…ANGO logoANGOAngioDynamics, In…ZBH logoZBHZimmer Biomet Hol…
Market CapShares × price$54M$1.2B$112.7B$469M$16.3B
Enterprise ValueMkt cap + debt − cash$48M$1.6B$123.5B$413M$23.3B
Trailing P/EPrice ÷ TTM EPS-1.53x-8.07x35.03x-13.58x23.48x
Forward P/EPrice ÷ next-FY EPS est.27.09x19.62x9.83x
PEG RatioP/E ÷ EPS growth rate2.36x
EV / EBITDAEnterprise value multiple3752.09x20.31x9.47x
Price / SalesMarket cap ÷ Revenue6.06x1.54x4.49x1.60x1.98x
Price / BookPrice ÷ Book value/share1.54x32.28x5.02x2.52x1.30x
Price / FCFMarket cap ÷ FCF422.56x26.31x11.09x
ZBH leads this category, winning 4 of 6 comparable metrics.

Profitability & Efficiency

SYK leads this category, winning 6 of 9 comparable metrics.

SYK delivers a 15.0% return on equity — every $100 of shareholder capital generates $15 in annual profit, vs $-4 for ATEC. NSPR carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to ATEC's 17.21x. On the Piotroski fundamental quality scale (0–9), ATEC scores 6/9 vs NSPR's 4/9, reflecting solid financial health.

MetricNSPR logoNSPRInspireMD, Inc.ATEC logoATECAlphatec Holdings…SYK logoSYKStryker Corporati…ANGO logoANGOAngioDynamics, In…ZBH logoZBHZimmer Biomet Hol…
ROE (TTM)Return on equity-116.2%-4.4%+15.0%-15.7%+5.8%
ROA (TTM)Return on assets-88.7%-15.8%+6.9%-10.3%+3.3%
ROICReturn on invested capital-108.3%-12.6%+11.4%-22.9%+5.4%
ROCEReturn on capital employed-100.4%-13.7%+13.0%-18.6%+6.9%
Piotroski ScoreFundamental quality 0–946655
Debt / EquityFinancial leverage0.04x17.21x0.66x0.59x
Net DebtTotal debt minus cash-$7M$459M$10.8B-$56M$6.9B
Cash & Equiv.Liquid assets$9M$161M$4.0B$56M$592M
Total DebtShort + long-term debt$2M$620M$14.9B$0$7.5B
Interest CoverageEBIT ÷ Interest expense-373.27x-3.29x6.72x-258.19x4.08x
SYK leads this category, winning 6 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

ANGO leads this category, winning 3 of 6 comparable metrics.

A $10,000 investment in SYK five years ago would be worth $12,152 today (with dividends reinvested), compared to $2,302 for NSPR. Over the past 12 months, ANGO leads with a +28.5% total return vs NSPR's -54.5%. The 3-year compound annual growth rate (CAGR) favors ANGO at 7.9% vs ATEC's -19.5% — a key indicator of consistent wealth creation.

MetricNSPR logoNSPRInspireMD, Inc.ATEC logoATECAlphatec Holdings…SYK logoSYKStryker Corporati…ANGO logoANGOAngioDynamics, In…ZBH logoZBHZimmer Biomet Hol…
YTD ReturnYear-to-date-37.6%-62.7%-15.2%-11.1%-7.1%
1-Year ReturnPast 12 months-54.5%-37.8%-22.5%+28.5%-10.4%
3-Year ReturnCumulative with dividends-21.6%-47.8%+5.5%+25.8%-37.2%
5-Year ReturnCumulative with dividends-77.0%-48.7%+21.5%-53.3%-47.3%
10-Year ReturnCumulative with dividends-100.0%+225.4%+187.1%-9.2%-17.8%
CAGR (3Y)Annualised 3-year return-7.8%-19.5%+1.8%+7.9%-14.4%
ANGO leads this category, winning 3 of 6 comparable metrics.

Risk & Volatility

Evenly matched — SYK and ANGO each lead in 1 of 2 comparable metrics.

SYK is the less volatile stock with a 0.55 beta — it tends to amplify market swings less than ANGO's 1.32 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ANGO currently trades 80.6% from its 52-week high vs ATEC's 33.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricNSPR logoNSPRInspireMD, Inc.ATEC logoATECAlphatec Holdings…SYK logoSYKStryker Corporati…ANGO logoANGOAngioDynamics, In…ZBH logoZBHZimmer Biomet Hol…
Beta (5Y)Sensitivity to S&P 5000.85x1.13x0.55x1.32x0.65x
52-Week HighHighest price in past year$2.93$23.29$404.87$13.99$108.29
52-Week LowLowest price in past year$1.02$6.85$289.91$8.36$79.83
% of 52W HighCurrent price vs 52-week peak+39.6%+33.3%+72.7%+80.6%+77.0%
RSI (14)Momentum oscillator 0–10034.426.824.354.034.3
Avg Volume (50D)Average daily shares traded98K3.0M2.1M395K2.2M
Evenly matched — SYK and ANGO each lead in 1 of 2 comparable metrics.

Analyst Outlook

Evenly matched — SYK and ZBH each lead in 1 of 2 comparable metrics.

Analyst consensus: ATEC as "Buy", SYK as "Buy", ANGO as "Hold", ZBH as "Hold". Consensus price targets imply 222.6% upside for ATEC (target: $25) vs 17.4% for ZBH (target: $98). For income investors, ZBH offers the higher dividend yield at 1.15% vs SYK's 1.14%.

MetricNSPR logoNSPRInspireMD, Inc.ATEC logoATECAlphatec Holdings…SYK logoSYKStryker Corporati…ANGO logoANGOAngioDynamics, In…ZBH logoZBHZimmer Biomet Hol…
Analyst RatingConsensus buy/hold/sellBuyBuyHoldHold
Price TargetConsensus 12-month target$25.00$403.69$16.50$97.90
# AnalystsCovering analysts16501142
Dividend YieldAnnual dividend ÷ price+1.1%+1.1%
Dividend StreakConsecutive years of raises340
Dividend / ShareAnnual DPS$3.36$0.96
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%0.0%+0.4%+3.0%
Evenly matched — SYK and ZBH each lead in 1 of 2 comparable metrics.
Key Takeaway

SYK leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ZBH leads in 1 (Valuation Metrics). 2 tied.

Best OverallStryker Corporation (SYK)Leads 2 of 6 categories
Loading custom metrics...

NSPR vs ATEC vs SYK vs ANGO vs ZBH: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is NSPR or ATEC or SYK or ANGO or ZBH a better buy right now?

For growth investors, InspireMD, Inc.

(NSPR) is the stronger pick with 28. 1% revenue growth year-over-year, versus -3. 8% for AngioDynamics, Inc. (ANGO). Zimmer Biomet Holdings, Inc. (ZBH) offers the better valuation at 23. 5x trailing P/E (9. 8x forward), making it the more compelling value choice. Analysts rate Alphatec Holdings, Inc. (ATEC) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — NSPR or ATEC or SYK or ANGO or ZBH?

On trailing P/E, Zimmer Biomet Holdings, Inc.

(ZBH) is the cheapest at 23. 5x versus Stryker Corporation at 35. 0x. On forward P/E, Zimmer Biomet Holdings, Inc. is actually cheaper at 9. 8x.

03

Which is the better long-term investment — NSPR or ATEC or SYK or ANGO or ZBH?

Over the past 5 years, Stryker Corporation (SYK) delivered a total return of +21.

5%, compared to -77. 0% for InspireMD, Inc. (NSPR). Over 10 years, the gap is even starker: ATEC returned +225. 4% versus NSPR's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — NSPR or ATEC or SYK or ANGO or ZBH?

By beta (market sensitivity over 5 years), Stryker Corporation (SYK) is the lower-risk stock at 0.

55β versus AngioDynamics, Inc. 's 1. 32β — meaning ANGO is approximately 142% more volatile than SYK relative to the S&P 500. On balance sheet safety, InspireMD, Inc. (NSPR) carries a lower debt/equity ratio of 4% versus 17% for Alphatec Holdings, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — NSPR or ATEC or SYK or ANGO or ZBH?

By revenue growth (latest reported year), InspireMD, Inc.

(NSPR) is pulling ahead at 28. 1% versus -3. 8% for AngioDynamics, Inc. (ANGO). On earnings-per-share growth, the picture is similar: AngioDynamics, Inc. grew EPS 81. 9% year-over-year, compared to -19. 9% for Zimmer Biomet Holdings, Inc.. Over a 3-year CAGR, ATEC leads at 29. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — NSPR or ATEC or SYK or ANGO or ZBH?

Stryker Corporation (SYK) is the more profitable company, earning 12.

9% net margin versus -543. 3% for InspireMD, Inc. — meaning it keeps 12. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SYK leads at 19. 5% versus -547. 0% for NSPR. At the gross margin level — before operating expenses — ATEC leads at 69. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is NSPR or ATEC or SYK or ANGO or ZBH more undervalued right now?

On forward earnings alone, Zimmer Biomet Holdings, Inc.

(ZBH) trades at 9. 8x forward P/E versus 27. 1x for Alphatec Holdings, Inc. — 17. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ATEC: 222. 6% to $25. 00.

08

Which pays a better dividend — NSPR or ATEC or SYK or ANGO or ZBH?

In this comparison, ZBH (1.

1% yield), SYK (1. 1% yield) pay a dividend. NSPR, ATEC, ANGO do not pay a meaningful dividend and should not be held primarily for income.

09

Is NSPR or ATEC or SYK or ANGO or ZBH better for a retirement portfolio?

For long-horizon retirement investors, Stryker Corporation (SYK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

55), 1. 1% yield, +187. 1% 10Y return). Both have compounded well over 10 years (SYK: +187. 1%, ANGO: -9. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between NSPR and ATEC and SYK and ANGO and ZBH?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: NSPR is a small-cap high-growth stock; ATEC is a small-cap high-growth stock; SYK is a mid-cap quality compounder stock; ANGO is a small-cap quality compounder stock; ZBH is a mid-cap quality compounder stock. SYK, ZBH pay a dividend while NSPR, ATEC, ANGO do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

NSPR

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 30%
  • Gross Margin > 17%
Run This Screen
Stocks Like

ATEC

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 53%
Run This Screen
Stocks Like

SYK

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 7%
Run This Screen
Stocks Like

ANGO

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Gross Margin > 32%
Run This Screen
Stocks Like

ZBH

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 5%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform NSPR and ATEC and SYK and ANGO and ZBH on the metrics below

Revenue Growth>
%
(NSPR: 61.6% · ATEC: -100.0%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.